United Therapeutics Corp (NASDAQ: UTHR) is 63.70% higher on its value in year-to-date trading and has touched a low of $208.62 and a high of $417.82 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The UTHR stock was last observed hovering at around $363.65 in the last trading session, with the day’s loss setting it -2.78%.
Currently trading at $360.87, the stock is -1.82% and -2.68% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.14 million and changing -0.76% at the moment leaves the stock 13.67% off its SMA200. UTHR registered 64.41% gain for a year compared to 6-month gain of 12.85%. The firm has a 50-day simple moving average (SMA 50) of $370.7474 and a 200-day simple moving average (SMA200) of $316.91626.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -3.47% loss in the last 1 month and extending the period to 3 months gives it a 0.12%, and is -5.20% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.35% over the week and 2.60% over the month.
United Therapeutics Corp (UTHR) has around 1168 employees, a market worth around $15.99B and $2.76B in sales. Current P/E ratio is 15.85 and Fwd P/E is 12.43. Profit margin for the company is 40.31%. Distance from 52-week low is 72.98% and -13.63% from its 52-week high. The company has generated returns on investments over the last 12 months (18.21%).
with sales reaching $743.01M over the same period.The EPS is expected to grow by 22.72% this year, but quarterly earnings will post 23.70% year-over-year. Quarterly sales are estimated to grow 20.87% in year-over-year returns.
United Therapeutics Corp (UTHR) Top Institutional Holders
921.0 institutions hold shares in United Therapeutics Corp (UTHR), with institutional investors hold 102.01% of the company’s shares. The shares outstanding are 44.62M, and float is at 43.83M with Short Float at 5.12%. Institutions hold 100.13% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 5.47 million shares valued at $1.74 billion. The investor’s holdings represent 11.6362% of the UTHR Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 4.42 million shares valued at $1.41 billion to account for 9.402 of the shares outstanding. The other top investors are WELLINGTON MANAGEMENT GROUP LLP which holds 3.29 million shares representing 6.99% and valued at over $1.05 billion, while AVORO CAPITAL ADVISORS LLC holds 6.0827 of the shares totaling 2.86 million with a market value of $910.7 million.
United Therapeutics Corp (UTHR) Insider Activity
The most recent transaction is an insider sale by SULLIVAN LOUIS W, the company’s Director. SEC filings show that SULLIVAN LOUIS W sold 26,209 shares of the company’s common stock on Dec 18 ’24 at a price of $373.22 per share for a total of $9.78 million. Following the sale, the insider now owns 5051.0 shares.
Still, SEC filings show that on Dec 16 ’24, BENKOWITZ MICHAEL (PRESIDENT AND COO) disposed off 10,000 shares at an average price of $370.14 for $3.7 million. The insider now directly holds 0 shares of United Therapeutics Corp (UTHR).
